Research Article
No access
Published Online: 19 March 2009

Severe Visual Loss After a Single Dose of Vincristine in a Patient with Spinal Cord Astrocytoma

Publication: Journal of Ocular Pharmacology and Therapeutics
Volume 4, Issue Number 2

ABSTRACT

A case of severe visual loss following a single dose of vincristine is described. The primary pathology was a spinal cord astrocytoma, grade II, with no intracranial extension. Visual loss after a single small dose of vincristine has never been reported. While peripheral neuropathy and cranial nerve involvement is common, optic neuropathy is extremely rare. The literature of vincristine optic nerve toxicity is reviewed. Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

cover image Journal of Ocular Pharmacology and Therapeutics
Journal of Ocular Pharmacology and Therapeutics
Volume 4Issue Number 2Summer 1988
Pages: 117 - 121

History

Published online: 19 March 2009
Published in print: Summer 1988

Permissions

Request permissions for this article.

Authors

Affiliations

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/EPUB

Figures

Tables

Media

Share

Share

Copy the content Link

Share on social media

Back to Top